Statement from John G. Boyle, IDF President & CEO as part of the IDF National Summit
Since the onset of COVID-19, our team at IDF has continued to monitor the impact the pandemic is having on global and domestic source plasma supply levels. In particular, we are concerned about how the drop in supply will translate to reduced availability of immunoglobulin (Ig) products, which are lifesaving, lifelong treatments for people with primary immunodeficiencies (PI), specifically those who have antibody deficiencies.
Estimates on the decrease in source plasma donations over the past eight months vary, but we know that a global Ig shortage is a real possibility. As we continue to monitor what’s happening, we are growing increasingly fearful of the ways this shortage will affect those who rely on Ig or other plasma-derived therapies.
IDF has engaged various stakeholders on an international level to get any details we can. While specifics are in short supply, we know others share our concerns.
Within the last week, the Plasma Protein Therapeutics Association (PPTA), shared a statement regarding their assessment of source plasma levels and the urgent need for donations.
There have also been several recent news articles regarding the shortage of source plasma, highlighting both the perspective of pharmaceutical companies and patients who rely on plasma-derived therapies.
Please know we will continue to share any new information we have on this worrisome and evolving situation with the PI community as soon as we have definitive updates.
While we wait to get more details, one thing we know for sure is we can all help make a difference by strongly encouraging plasma donations. It’s our only true path forward here. At IDF, we are thrilled with our new Plasma Hero initiative that not only honors existing plasma donors but also serves as a resource for anyone considering plasma donation. Please take a few minutes to visit www.plasmahero.org to learn more. Most importantly, though, please share it with your friends, family, and social circles.
Thank you for your continued patience during these trying times. Our team will remain vigilant in seeking information and proactively arming our PI community with knowledge when we know more.
For information about Ig products, go to www.primaryimmune.org/ig.
This content should not be used as a substitute for professional medical advice. In all cases, patients and caregivers should consult their healthcare providers. Each patient’s condition and treatment is unique. The benefits and risks of any treatment should be discussed with the patient’s provider.